Coenzyme Q10 (Ubiquinone) — ≥98% HPLC Nutraceutical/Cosmetic Grade, ≥99% Pharma Grade & Ubiquinol (Reduced Form) Supplier
Coenzyme Q10 (Ubiquinone, CAS 303-98-0 / Ubiquinol, CAS 992-78-9) — the essential mitochondrial ETC electron carrier: Complex I→III Q-cycle electron shuttle, the most powerful endogenous lipid-soluble antioxidant, and the rate-limiting cofactor for ATP production. Fermentation-derived from Schizosaccharomyces pombe yeast — natural all-trans configuration identical to the endogenous human form, with 30–50% higher bioavailability than synthetic CoQ10. Available in ubiquinone (≥98% HPLC Nutraceutical/Cosmetic Grade and ≥99% Pharma Grade) and ubiquinol (reduced/active form, ≥98%). Level I evidence for chronic heart failure (Q-SYMBIO: 43% cardiovascular mortality reduction). ISO 9001:2015, ISO 22000, HACCP, FDA, HALAL, KOSHER, Non-GMO certified. USP monograph compliant. Bulk manufacturer and wholesale supplier — premium Coenzyme Q10 from UPOR Biotech.
Request a QuoteProduct Overview
Coenzyme Q10 (CoQ10, INCI: Ubiquinone, CAS 303-98-0 [Ubiquinone] / CAS 992-78-9 [Ubiquinol], C₅₉H₉₀O₄, MW 863.34 g/mol) is a fat-soluble, vitamin-like benzoquinone that functions as the essential electron carrier in the mitochondrial electron transport chain (ETC) — the biochemical engine that produces approximately 95% of cellular ATP. Within the inner mitochondrial membrane, CoQ10 operates through the Q-cycle mechanism: ubiquinone (oxidized form, Q) accepts electrons from Complex I (NADH dehydrogenase) and Complex II (succinate dehydrogenase). The reduction proceeds in two sequential one-electron steps — first forming the ubisemiquinone radical intermediate (QH•), then the fully reduced ubiquinol (QH₂). Ubiquinol diffuses laterally through the membrane lipid bilayer to Complex III (cytochrome bc₁ complex), where it donates electrons through the bifurcated Q-cycle at the Q₀ and Qₛ binding sites: one electron proceeds to cytochrome c via the Rieske iron-sulfur protein and cytochrome c₁ (high-potential chain), while the second electron is recycled back to reduce another ubiquinone molecule (low-potential chain). This elegant redox cycling doubles the proton-pumping stoichiometry, maximizing the proton gradient that drives ATP synthase (Complex V) to phosphorylate ADP → ATP. The ubiquinone ⇄ ubiquinol redox cycle is the rate-limiting electron transfer step in mitochondrial oxidative phosphorylation.
Beyond its role as an ETC electron carrier, CoQ10 is the most powerful endogenous lipid-soluble antioxidant in the human body — ubiquinol directly neutralizes lipid peroxyl radicals, protects mitochondrial cardiolipin from peroxidation, regenerates vitamin E (α-tocopherol) from its oxidized tocopheroxyl radical form, and preserves LDL cholesterol from oxidative modification (a key initiating event in atherogenesis). Endogenous CoQ10 biosynthesis occurs via the mevalonate pathway — a multi-step process beginning with acetyl-CoA and proceeding through farnesyl pyrophosphate, requiring at least 15 genes (COQ1–COQ10 and associated regulatory factors). This is the same pathway targeted by HMG-CoA reductase inhibitors (statins): statins block the rate-limiting HMG-CoA reductase enzyme, reducing not only cholesterol synthesis but also CoQ10 biosynthesis, leading to a clinically documented 16–54% reduction in serum CoQ10 levels. This statin-induced CoQ10 depletion is a primary mechanism underlying statin-associated muscle symptoms (SAMS) and provides the clinical rationale for CoQ10 supplementation in statin users. Endogenous CoQ10 synthesis peaks around age 20–25 and declines steadily thereafter, with myocardial CoQ10 levels dropping approximately 50% by age 80 — correlating with age-related mitochondrial dysfunction, decreased ATP production, and increased oxidative damage. After age 40, the body’s enzymatic capacity to convert ubiquinone to ubiquinol (via NQO1, NAD(P)H-dependent quinone reductases, and other cytosolic reductases) declines significantly, making ubiquinol 3–8× more bioavailable than ubiquinone in older adults.
UPOR Biotech’s CoQ10 is produced via fermentation using Schizosaccharomyces pombe (fission yeast) — the preferred industrial production method yielding the natural all-trans configuration identical to endogenous human CoQ10. Fermentation-derived CoQ10 achieves 30–50% higher plasma AUC (area under the curve) compared to synthetic CoQ10 at equivalent doses, as confirmed by comparative pharmacokinetic studies. Synthetic CoQ10 (produced via solanesol oxidation or isoprene side-chain condensation) may contain cis-trans isomeric mixtures that the body cannot fully metabolize, resulting in lower bioavailability. The fermentation process uses non-GMO yeast strains under controlled conditions, yielding a product free from the solvent residues and isomeric impurities associated with chemical synthesis routes. CoQ10 from UPOR Biotech is USP monograph compliant and meets all compendial specifications for identity, purity, and potency.
As a leading Coenzyme Q10 manufacturer and bulk supplier, UPOR Biotech provides high-purity CoQ10 powder for B2B nutraceutical brands, dietary supplement manufacturers, sports nutrition companies, cosmetic formulators, and pharmaceutical developers worldwide. The global heart health supplement market — where CoQ10 is the dominant active ingredient — represents the single largest category in the dietary supplement industry, valued at over $20 billion and growing at 7–9% CAGR driven by aging populations, rising statin prescription rates, and consumer focus on cardiovascular prevention. Ubiquinol (reduced CoQ10) represents the premium market segment, commanding a 2–4× price premium over ubiquinone and positioned for the 40+ demographic, anti-aging formulations, and high-bioavailability product differentiation. OEM and private label formulations available with flexible MOQ starting at 1 kg. Free sample available for qualified B2B buyers. Every shipment includes full documentation: COA, MSDS, HPLC chromatogram, and stability data. Synergistic blending with PQQ, NAD+ precursors (NMN/NR), and mitochondrial nutrients available for comprehensive mitochondrial health formulations.
CoQ10 vs PQQ vs NAD+ — The Mitochondrial Health Triad: Why CoQ10 Is the Electron Carrier That Powers ATP Synthase
The three leading mitochondrial health bioactives — Coenzyme Q10, PQQ (pyrroloquinoline quinone), and NAD+ precursors (NMN, NR) — target distinct yet synergistically complementary nodes in mitochondrial biology, forming the Mitochondrial Health Triad. Coenzyme Q10 (Ubiquinone/Ubiquinol) is the essential electron carrier: it physically shuttles electrons between ETC Complexes I/II and Complex III through the Q-cycle, enabling the proton gradient that powers ATP synthase. CoQ10 is the actual electron-transferring molecule — without it, the ETC circuit is broken and oxidative phosphorylation ceases. PQQ (Pyrroloquinoline Quinone) is a mitochondrial biogenesis activator: it stimulates the PGC-1α → NRF-1/NRF-2 → TFAM pathway to create new mitochondria (mitochondrial biogenesis), increasing total cellular oxidative capacity by 20–30%. PQQ also functions as a redox cofactor with exceptionally high catalytic cycling capacity — a single PQQ molecule can catalyze thousands of redox cycles. NAD+ precursors (NMN, NR) replenish the NAD+ pool that serves as the initial electron acceptor at Complex I (NADH dehydrogenase) and as a substrate for sirtuins (SIRT1–7) and PARPs regulating metabolism, DNA repair, and longevity pathways. The clinical synergy is clear: PQQ increases mitochondrial quantity, CoQ10 improves mitochondrial quality and electron transfer efficiency within each mitochondrion, and NAD+ provides the initial electron source and metabolic signaling. Notably, CoQ10 is the only member of this triad that is directly depleted by statin medications (via mevalonate pathway blockade) — a critical consideration for the 200+ million global statin users. UPOR Biotech provides all three triad members as standalone bioactives and can create custom pre-blended formulations combining CoQ10 + PQQ + NAD+ precursors for comprehensive mitochondrial health supplement products.
Technical Specifications
| Property | Specification |
|---|---|
| Product Name | Coenzyme Q10 Powder — Ubiquinone (≥98% Nutraceutical/Cosmetic, ≥99% Pharma) / Ubiquinol (Reduced/Active Form, ≥98%) |
| INCI Name | Ubiquinone (ubiquinone form); Ubiquinol (reduced form) |
| Common Name / Synonyms | CoQ10; Ubiquinone; Coenzyme Q10; Ubidecarenone; Vitamin Q10; Mitoquinone; 2,3-Dimethoxy-5-methyl-6-decaprenyl-1,4-benzoquinone |
| CAS Number (Ubiquinone) | 303-98-0 |
| CAS Number (Ubiquinol) | 992-78-9 |
| Molecular Formula & Molecular Weight | C₅₉H₉₀O₄ / 863.34 g/mol |
| Source | Fermentation-derived (yeast — Schizosaccharomyces pombe) — natural all-trans configuration identical to endogenous human CoQ10. Synthetic route also available upon request. |
| Key Advantage | Essential mitochondrial ETC electron carrier (Complex I/II → Complex III Q-cycle); most powerful endogenous lipid-soluble antioxidant; rate-limiting cofactor for ATP production. Fermentation-derived all-trans isomer with 30–50% higher plasma AUC vs synthetic CoQ10. |
| Appearance (Ubiquinone) | Yellow to orange crystalline powder |
| Appearance (Ubiquinol) | White to off-white crystalline powder (reduced/active form — oxidation-sensitive, requires inert atmosphere packaging) |
| Assay — Ubiquinone (Nutraceutical/Cosmetic Grade) | ≥98.0% (HPLC, anhydrous basis) — USP monograph compliant |
| Assay — Ubiquinone (Pharma Grade) | ≥99.0% (HPLC, anhydrous basis) — USP monograph compliant |
| Assay — Ubiquinol (Reduced Form) | ≥98.0% (HPLC, anhydrous basis) — Manufacturer qualification standard with electrochemical detection (HPLC-ECD) |
| Ubiquinone-Related Compounds (Impurity Profile) | Impurity A (2,3-dimethoxy-5-methyl-1,4-benzoquinone) ≤0.5%; Impurity B (ubiquinone-9 / CoQ9) ≤0.5%; Impurity C (ubichromenol) ≤0.5%; any unspecified impurity ≤0.2%; total impurities ≤1.0% (USP monograph limits) |
| Ubiquinol / Ubiquinone Ratio (Ubiquinol Grade) | ≥95% reduced form (ubiquinol); ≤5% oxidized form (ubiquinone) — by HPLC with electrochemical detection (HPLC-ECD) |
| Identification | IR spectrum conforms to USP Ubidecarenone RS; HPLC retention time matches reference standard; UV λmax 275 nm (ethanol, ubiquinone); λmax 290 nm (ethanol, ubiquinol) |
| Loss on Drying | ≤0.2% (105°C, 2 hours) — USP method |
| Residue on Ignition | ≤0.1% |
| Melting Point (Ubiquinone) | 48 – 52°C |
| Solubility | Practically insoluble in water; freely soluble in chloroform, acetone, and diethyl ether; sparingly soluble in ethanol; soluble in lipophilic solvents and oils — requires emulsification or lipid-based delivery systems for aqueous formulations |
| Heavy Metals & Elemental Impurities | Total heavy metals ≤10 ppm (as Pb); Pb ≤2 ppm; As ≤1 ppm; Hg ≤1 ppm; Cd ≤1 ppm (USP <232> / ICH Q3D compliant) |
| Microbial Limits | TAMC ≤100 CFU/g; TYMC ≤10 CFU/g (USP <61> / EP <2.6.12>); Pathogens (E. coli, Salmonella, S. aureus, P. aeruginosa) — Absent in 10 g (USP <62> / EP <2.6.13>) |
| Residual Solvents | USP <467> / EP <5.4> / ICH Q3C Class 3 compliant; ethanol ≤5000 ppm for fermentation-derived material |
| Recommended Usage (Nutraceutical / Oral) | 30 – 300 mg/day oral (ubiquinone); 50 – 200 mg/day oral (ubiquinol). Typical formulation: 100–200 mg softgel (ubiquinone) or 50–100 mg softgel (ubiquinol). Lipid-based delivery (oil suspension, liposomal, or emulsified) recommended for optimal absorption — bioavailability enhanced 2–3× with dietary fat co-administration. |
| Recommended Usage (Cosmetic / Topical) | 0.01 – 1.0% in leave-on anti-aging formulations. Incorporate into oil phase or use liposomal/lipid nanoparticle delivery for epidermal penetration to viable dermal layers. |
| Grade / Standards | Nutraceutical/Cosmetic Grade (≥98% HPLC, USP monograph compliant); Pharma Grade (≥99% HPLC, USP monograph compliant); Ubiquinol Grade (≥98% reduced form, manufacturer qualification standard with HPLC-ECD) |
| Certifications | ISO 9001:2015, ISO 22000, HACCP, FDA Facility Registration, HALAL, KOSHER, Non-GMO, BSE/TSE-Free |
| Packaging | 1 kg / 5 kg / 10 kg vacuum-sealed aluminum foil bags with PE liner under nitrogen headspace (ubiquinol); 25 kg fiber drums with double PE liner; light-protective and oxygen-barrier packaging essential for ubiquinol stability. Desiccant and oxygen absorber included per unit. |
| Storage | 2 – 8°C refrigerated (ubiquinol — required); 15 – 25°C (ubiquinone); tightly sealed in original light-protective container under inert atmosphere (N₂ or argon); protect from light, moisture, and oxygen at all times |
| Shelf Life | 3 years (ubiquinone) / 2 years (ubiquinol) from date of manufacture under recommended storage conditions |
Key Benefits — Coenzyme Q10 (Ubiquinone)
Mitochondrial ETC Electron Carrier — ATP Production Rate-Limiting Cofactor
CoQ10 is the essential electron shuttle in the Q-cycle: it accepts electrons from Complex I (NADH) and Complex II (FADH₂) and transfers them to Complex III, enabling the proton gradient that drives ATP synthase to produce ~95% of cellular ATP. The ubiquinone ⇄ ubiquinol redox cycle is the single rate-limiting electron transfer step in oxidative phosphorylation — without adequate CoQ10, mitochondrial ATP production collapses, affecting the heart (highest mitochondrial density of any organ at ~114 μg/g tissue), brain, and skeletal muscle first.
Complex I→III Electron CarrierLevel I Evidence for Chronic Heart Failure — 43% Cardiovascular Mortality Reduction
The landmark Q-SYMBIO randomized controlled trial (n=420, 2-year follow-up, Mortensen et al. 2014, JACC Heart Failure) demonstrated that CoQ10 supplementation (100 mg TID) reduced cardiovascular mortality by 43% (p=0.005) and all-cause mortality by 42% (p=0.015) in chronic heart failure patients. CoQ10 improves left ventricular ejection fraction (LVEF +3–6%), reduces NYHA functional class, and decreases CHF hospitalization rates. The 2022 AHA Scientific Statement recognizes CoQ10 as the best-documented adjunctive CHF nutraceutical. Additional cardiovascular benefits: endothelial function improvement, systolic BP reduction (3–5 mmHg), post-MI recovery support, and atrial fibrillation prevention.
Level I CHF EvidenceMost Powerful Endogenous Lipid-Soluble Antioxidant — Membrane Protection + Vitamin E Regeneration
Ubiquinol (reduced CoQ10) is the most potent lipid-soluble antioxidant synthesized by the human body — it directly neutralizes lipid peroxyl radicals within mitochondrial and cellular membranes, protects cardiolipin (the signature phospholipid of the inner mitochondrial membrane) from peroxidation, regenerates vitamin E (α-tocopherol) from its oxidized tocopheroxyl radical form back to active antioxidant state, and prevents LDL cholesterol oxidative modification (the initiating event in atherogenesis). CoQ10 antioxidant capacity is 5–10× greater than vitamin E on a molar basis in lipid membrane environments and is the only endogenously synthesized lipid-soluble antioxidant.
Lipid-Soluble AntioxidantUbiquinol 3–8× Bioavailability After Age 40 — Statin Depletion Recovery
Ubiquinol (reduced/active form, CAS 992-78-9) is 3–8× more bioavailable than ubiquinone in adults over age 40 because it bypasses the age-declined enzymatic conversion step (NQO1 and NAD(P)H-dependent cytosolic reductases). Statins deplete CoQ10 by 16–54% via mevalonate pathway blockade at HMG-CoA reductase — CoQ10 supplementation alleviates statin-associated muscle symptoms (SAMS) without interfering with cholesterol-lowering efficacy. Fermentation-derived all-trans ubiquinone achieves 30–50% higher plasma AUC than synthetic CoQ10. UPOR Biotech provides both ubiquinone and ubiquinol forms for flexible formulation strategies across demographic segments and price points.
Ubiquinol ≥98% AvailableApplications
Heart Health & Cardiovascular Supplement Formulations
CoQ10 is the cornerstone active for heart health dietary supplements — the single largest global supplement category valued at over $20 billion. Formulate standalone CoQ10 softgels (100–300 mg ubiquinone or 50–200 mg ubiquinol), heart health complexes with omega-3 fatty acids, and comprehensive cardiovascular support blends. Level I CHF evidence from the Q-SYMBIO trial provides powerful marketing differentiation. OEM and private label formulations available with flexible MOQ starting at 1 kg.
Anti-Aging & Longevity Nutraceutical Products
CoQ10 at 100–200 mg/day (ubiquinone) or 50–100 mg/day (ubiquinol) in anti-aging and longevity supplement formulations. Ubiquinol is the premium positioning for the 40+ demographic — 3–8× higher bioavailability where endogenous conversion capacity has declined most. Combine with PQQ (mitochondrial biogenesis) and NAD+ precursors (NMN/NR) for the complete Mitochondrial Health Triad for comprehensive cellular rejuvenation product lines.
Statin Support & Muscle Recovery Nutraceuticals
CoQ10 at 100–200 mg/day in statin companion supplements targeting the 200+ million global statin users. Addresses statin-associated muscle symptoms (SAMS) by replenishing mevalonate pathway-depleted CoQ10 without affecting cholesterol-lowering efficacy. Combine with magnesium, vitamin D, and L-carnitine for comprehensive statin support formulations. Strong clinical narrative and established market demand — statin users are the single largest CoQ10 consumer segment.
Sports Nutrition & Endurance / Energy Performance Products
CoQ10 at 100–300 mg in pre-workout, intra-workout, and recovery formulations for athletes and active consumers. Improves mitochondrial ATP output during sustained exercise, reduces exercise-induced oxidative stress, enhances VO₂max, and accelerates post-exercise muscle recovery. Particularly effective for endurance athletes (cyclists, runners, triathletes) and aging athletes experiencing natural CoQ10 decline. Combine with creatine, beta-alanine, and electrolytes for comprehensive performance formulations.
Anti-Aging Skin Care & Cosmeceutical Topical Formulations
CoQ10 (ubiquinone or ubiquinol) at 0.01–1.0% in anti-aging serums, creams, and cosmeceutical formulations. Protects against UV-induced oxidative damage in epidermal and dermal layers, reduces wrinkle depth (clinically demonstrated in randomized split-face studies), supports dermal fibroblast mitochondrial function and ATP output, preserves collagen and elastin integrity, and improves skin barrier function. Incorporate via lipid-based delivery systems (liposomes, nanoemulsions, or lipid nanoparticles) for optimal epidermal penetration to viable dermal layers.
Fertility Support & Reproductive Health Nutraceuticals
CoQ10 at 100–600 mg/day in male and female fertility support formulations. Improves sperm motility, concentration, and morphology by enhancing mitochondrial energy production in sperm cells (highest mitochondrial density per cell in the human body). In female fertility, supports oocyte mitochondrial function and oocyte quality — especially relevant for the 35+ demographic where oocyte CoQ10 levels naturally decline, correlating with age-related fertility reduction. Ubiquinol form preferred for fertility applications due to superior bioavailability and direct antioxidant activity in reproductive tissues.
Frequently Asked Questions
Coenzyme Q10 (CoQ10, Ubiquinone, CAS 303-98-0, C₅₉H₉₀O₄, MW 863.34 g/mol) is a fat-soluble vitamin-like benzoquinone that serves as the essential electron carrier in the mitochondrial electron transport chain (ETC). Within the inner mitochondrial membrane, CoQ10 shuttles electrons from Complex I (NADH dehydrogenase) and Complex II (succinate dehydrogenase) to Complex III (cytochrome bc₁ complex) through the Q-cycle mechanism: ubiquinone (oxidized) sequentially accepts two electrons — first one to form the ubisemiquinone radical intermediate, then a second to form ubiquinol (fully reduced). Ubiquinol diffuses laterally through the lipid bilayer to Complex III, donating electrons at the Q₀ and Qₛ binding sites, driving proton pumping across the membrane. This proton gradient powers ATP synthase (Complex V) to produce ~95% of cellular ATP. The ubiquinone ⇄ ubiquinol redox cycle is the rate-limiting step in oxidative phosphorylation. CoQ10 is also the most powerful endogenous lipid-soluble antioxidant, protecting mitochondrial cardiolipin, LDL cholesterol, and cellular membranes from oxidative damage. Endogenous CoQ10 synthesis peaks at age 20–25 and declines ~50% in myocardial tissue by age 80. UPOR Biotech provides fermentation-derived (S. pombe) CoQ10 in ubiquinone (≥98% / ≥99%) and ubiquinol (≥98% reduced) grades — the natural all-trans configuration identical to human CoQ10 with 30–50% higher plasma AUC than synthetic CoQ10.
CoQ10 delivers four clinically validated benefit domains: (1) Heart Health — Level I evidence (highest level) from the landmark Q-SYMBIO RCT (n=420, 2-year follow-up, JACC Heart Failure 2014) showing 43% reduction in cardiovascular mortality and 42% reduction in all-cause mortality in CHF patients at 300 mg/day. Improves LVEF (+3–6%), NYHA functional class, endothelial function, and systolic blood pressure. The 2022 AHA Scientific Statement recognizes CoQ10 as the best-documented adjunctive CHF nutraceutical. (2) Anti-Aging / Longevity — CoQ10 levels decline with age (~50% myocardial reduction by age 80). Ubiquinol is 3–8× more bioavailable after age 40 when endogenous conversion capacity declines. Restores mitochondrial energetics, reduces oxidative stress biomarkers (8-OHdG, F2-isoprostanes, MDA), and supports healthy aging at the cellular level. (3) Statin Recovery — statins deplete CoQ10 by 16–54% via mevalonate pathway blockade; CoQ10 alleviates statin-associated muscle symptoms (SAMS) without affecting cholesterol-lowering efficacy. (4) Skin Care — topical CoQ10 at 0.01–1.0% protects against UV-induced oxidative damage, reduces wrinkle depth (clinically demonstrated in split-face studies), supports dermal fibroblast mitochondrial function, and preserves collagen and elastin in anti-aging cosmeceuticals.
Ubiquinone (CAS 303-98-0) and ubiquinol (CAS 992-78-9) are the two redox states of Coenzyme Q10 that form the essential Q-cycle redox pair. Ubiquinone is the oxidized form — a yellow-orange crystalline powder that serves as the electron acceptor in the mitochondrial ETC, receiving electrons from Complex I and II. Ubiquinol is the reduced, active form — it carries electrons to Complex III AND functions as the body’s most powerful lipid-soluble antioxidant, directly neutralizing lipid peroxyl radicals. The two forms continuously interconvert: ubiquinone + 2e⁻ + 2H⁺ ⇄ ubiquinol (the Q-cycle). For absorption: in healthy individuals under age 25, ubiquinone is efficiently converted to ubiquinol endogenously and absorption is comparable between forms. However, after age 40, the enzymatic conversion capacity (NQO1, NAD(P)H-dependent quinone reductases, and cytosolic thioredoxin reductases) declines significantly. In older adults, ubiquinol demonstrates 3–8× higher bioavailability because it requires no conversion step. Ubiquinol is a white to off-white powder that is more oxidation-sensitive — it requires nitrogen-blanketed packaging, oxygen absorbers, and refrigerated storage (2–8°C). UPOR Biotech provides both forms — ubiquinone (≥98% Nutraceutical/Cosmetic and ≥99% Pharma grades) and ubiquinol (≥98% reduced form) — enabling flexible formulation strategies across demographic segments, delivery systems, and market price points.
CoQ10, PQQ, and NAD+ precursors form the Mitochondrial Health Triad — three complementary bioactives targeting distinct mitochondrial nodes. CoQ10 is the essential electron carrier: it physically shuttles electrons between ETC Complexes I/II and III through the Q-cycle, enabling the proton gradient that drives ATP synthase. Without CoQ10, the electron circuit is broken and oxidative phosphorylation ceases. PQQ is a mitochondrial biogenesis activator: it stimulates PGC-1α → NRF-1/NRF-2 → TFAM pathways to create new mitochondria, increasing total cellular oxidative capacity by 20–30%. PQQ also functions as a redox cofactor with exceptionally high catalytic cycling capacity. NAD+ precursors (NMN, NR) replenish the NAD+ pool required at Complex I as the initial electron acceptor (NAD+ → NADH) and serve as substrates for sirtuins (SIRT1–7) and PARPs regulating metabolism, DNA repair, and longevity. Clinical synergy: PQQ increases mitochondrial quantity, CoQ10 improves quality and electron transfer efficiency, and NAD+ provides the electron source and metabolic signaling. CoQ10 is the only triad member directly depleted by statin medications — a critical clinical distinction for the 200+ million global statin users. UPOR Biotech provides all three bioactives as standalone ingredients and custom pre-blended Mitochondrial Health Triad formulations.
Every shipment includes: COA (HPLC purity ≥98.0% nutraceutical/cosmetic or ≥99.0% pharma grade, full impurity profile including ubiquinone-related compounds A/B/C per USP monograph, ubiquinol/ubiquinone ratio for ubiquinol grade by HPLC-ECD, cis/trans isomer ratio for fermentation material, heavy metals ≤10 ppm with Pb ≤2 / As ≤1 / Hg ≤1 / Cd ≤1 ppm, residual solvents per USP <467> / EP <5.4> / ICH Q3C, microbial panel per USP <61>/<62> and EP <2.6.12>/<2.6.13>), MSDS, HPLC Chromatogram (signed and dated, with peak identification, integration, and ubiquinone/ubiquinol peak resolution), USP Monograph Compliance Certificate (ubiquinone), Manufacturer Qualification Statement (ubiquinol), BSE/TSE-Free Statement, Non-GMO Statement, Allergen Statement, HALAL Certificate, KOSHER Certificate, ISO 22000 + HACCP, ISO 9001:2015, FDA Facility Registration, Stability Data (25°C/60%RH real-time 36-month and 40°C/75%RH accelerated 6-month with ubiquinol oxidation product monitoring by HPLC-ECD), and Complete Lot Traceability from fermentation batch to finished product. Free sample available for qualified B2B buyers. MOQ: 1 kg. All documents provided in English. DMF support available for pharma grade upon signed Confidentiality Agreement. Custom pre-blended CoQ10 + PQQ + NAD+ precursor formulations available upon request.